SCHEMBL25756692

SCHEMBL25756692

C#CCCOCCN[C@H]1CC[C@@H](N=[N+]=[N-])CC1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25785385 1.00 SMN1; SMN2 (0.31) SMN1; SMN2
SCHEMBL25032292 0.99 SMN1; SMN2 (0.33) SMN1; SMN2
SCHEMBL25756677 0.93 SMN1; SMN2 (0.30) SMN1; SMN2
SCHEMBL25784935 0.93
SCHEMBL25756683 0.93
SCHEMBL25784799 0.93 SMN1; SMN2 (0.30) SMN1; SMN2
SCHEMBL25756287 0.85
SCHEMBL25756328 0.85
SCHEMBL25756106 0.82
SCHEMBL25773279 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 SMN1; SMN2 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.